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BACKGROUND: Epidemiological studies have shown that both the estrogen dose and progestogen type of oral
contraceptives contribute to the increased risk of thrombosis in oral contraceptive users. Thrombin generation-
based activated protein C (APC) sensitivity is a global test for the net prothrombotic effect of oral contraceptives
and predicts the thrombotic risk. Our objective was to test the usefulness of sex hormone-binding globulin (SHBG)
as a marker for the thrombotic risk of an oral contraceptive. METHODS: We measured SHBG and APC resist-
ance in 156 healthy users of various types of oral contraceptives. RESULTS: Users of oral contraceptives with a
moderately increased risk of thrombosis (gestodene and desogestrel pills) had higher SHBG levels than users of
low-risk oral contraceptives containing levonorgestrel. Similarly, for higher doses of estrogen in oral contraceptives
we found higher SHBG levels. Women using oral contraceptives with the highest thrombotic risk (cyproterone
acetate pills) rendered the highest SHBG levels. Users of oral contraceptives containing gestodene, desogestrel or
cyproterone acetate were more resistant to APC than users of levonorgestrel pills. SHBG levels were positively
associated with the increased APC resistance. CONCLUSIONS: Our findings support the hypothesis that the effect
of an oral contraceptive on SHBG levels might be a marker for the thrombotic risk.
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Introduction
Epidemiological studies have shown that both the estrogen
dose as well as the progestogen type of oral contraceptives
contribute to the increased risk of venous thrombosis in oral
contraceptive users (Vandenbroucke et al., 2001). So called
‘high-dose’ oral contraceptives containing $50mg ethinyl-
estradiol are associated with a higher risk of thrombosis than
‘low-dose’ oral contraceptives containing 20–30mg ethinyl-
estradiol (Rosendaal et al., 2003). Further, combined oral
contraceptives containing the third-generation progestogens
gestodene and desogestrel or the progestogen cyproterone
acetate are more thrombogenic than oral contraceptives con-
taining the second-generation progestogen levonorgestrel
(Kemmeren et al., 2001; Vasilakis-Scaramozza and Jick,
2001).
Use of oral contraceptives causes changes in procoagulant,
anticoagulant and fibrinolytic parameters, resulting in a net
prothrombotic effect (Vandenbroucke et al., 2001). This pro-
thrombotic effect can be measured globally by a thrombin
generation-based APC resistance test (Rosing et al., 1999).
The test outcome predicts the risk of venous thrombosis, in
users of oral contraceptives as well as in non-users and men
(Tans et al., 2003). Supporting the epidemiological obser-
vations, users of oral contraceptives containing desogestrel,
gestodene or cyproterone acetate were found more resistant
to the anticoagulant action of activated protein C (APC) by
this test than users of oral contraceptives containing levonor-
gestrel (Rosing et al., 1999; van Vliet et al., 2004). We
found the same for users of a new oral contraceptive contain-
ing drospirenone, for which no post-marketing data are cur-
rently available, but which safety with regard to thrombosis
has been questioned (Sheldon, 2002; van Vliet et al., 2004).
Recently a literature study and a randomized controlled
trial postulated that the effect of an oral contraceptive on sex
hormone-binding globulin (SHBG) levels could be an indi-
cator for the thrombotic risk of that oral contraceptive (Odlind
et al., 2002; van Rooijen et al., 2004). SHBG produced in the
liver is a carrier protein for estrogen and testosterone.
Human Reproduction Vol.20, No.2 pp. 563–568, 2005 doi:10.1093/humrep/deh612
Advance Access publication November 11, 2004.
Human Reproduction vol. 20 no. 2 q European Society of Human Reproduction and Embryology 2004; all rights reserved 563
Estrogens cause a dose-related increase in SHBG, whereas
progestogens induce a decrease of SHBG, the extent of which
depends on both dose and type of progestogen (Anderson,
1974; El Makhzangy et al., 1979; van der Vange et al., 1990;
Knopp et al., 2001). The type-related differences in progesto-
gen-induced decrease of SHBG might be interpreted as differ-
ences in anti-estrogenic properties of progestogens. Thus, the
effect of an oral contraceptive on SHBG levels can be seen as
the sum of the estrogenic effect of ethinylestradiol and the
anti-estrogenic effect of the progestogen resulting in the total
estrogenicity of the pill (van Kammen et al., 1975; Odlind
et al., 2002).
The literature study demonstrated a relationship between
the known thrombotic risk of second-generation, third-gener-
ation and cyproterone acetate-containing oral contraceptives
and the effect of the various types of oral contraceptives on
SHBG (Odlind et al., 2002). In agreement with the increased
risk of thrombosis, gestodene- and desogestrel-containing
contraceptive pills were more estrogenic, i.e. increased
SHBG more, than levonorgestrel-containing pills (Odlind
et al., 2002). Oral contraceptives containing cyproterone
acetate were associated with the highest SHBG levels
(Odlind et al., 2002). A randomized controlled trial compar-
ing SHBG levels in women using desogestrel-containing oral
contraceptives and women using levonorgestrel-containing
oral contraceptives confirmed the higher levels of SHBG in
desogestrel-containing pill users (van Rooijen et al., 2004).
In addition, an association between SHBG levels and the
resistance to APC measured with the classical activated
partial thromboplastin time-based APC resistance test was
reported (van Rooijen et al., 2004).
To test the usefulness of SHBG as a marker for the throm-
botic risk of an oral contraceptive, we compared the plasma
levels of SHBG and the resistance to APC determined with a
thrombin generation-based APC resistance test in users of
oral contraceptives containing either second- or third-gener-
ation progestogens or drospirenone or cyproterone acetate.
Our a priori hypotheses were: (i) the plasma levels of SHBG
in women using oral contraceptives known to confer an
increased risk of venous thrombosis are higher than in
women using contraceptive pills with levonorgestrel; and (ii)
the resistance to APC in women using oral contraceptives
follows the same pattern and is associated with SHBG levels.
Materials and methods
Study design and participants
Healthy women using the same type of oral contraceptive for at
least four cycles were recruited by advertising in local newspapers,
public and university buildings, student houses, pharmacies and gen-
eral practitioners’ waiting rooms. Exclusion criteria were age (,18
years) and contraindications for oral contraceptive use as stated by
World Health Organization (1996). After inclusion, women
completed a standardized questionnaire covering questions on risk
factors for venous thrombosis. Blood samples were drawn between
days 18 and 21 of the menstrual cycle. After the blood donation,
drospirenone- or cyproterone acetate-containing oral contraceptive
users were requested to switch to a second-generation oral
contraceptive composed of 150mg levonorgestrel and 30mg ethiny-
lestradiol (Microgynon-30w; Schering) and second- or third-gener-
ation oral contraceptive users were asked to switch to the
drospirenone-containing oral contraceptive. A second blood sample
was taken between days 18 and 21 of the fourth cycle after the
change of type of oral contraceptive.
The Medical Ethics Committee of the Leiden University Medical
Center, Leiden, The Netherlands approved the study. All volunteers
gave written informed consent.
Risk ranking per oral contraceptive
Based on the risk of thrombosis reported in the literature, we can
rank oral contraceptives by estrogen dose and progestogen type.
High-dose oral contraceptives containing $50mg ethinylestradiol
have been associated with a higher risk of thrombosis than low-dose
oral contraceptives containing 20–30mg ethinylestradiol (Gerstman
et al., 1991). Data from the ongoing Multiple Environmental and
Genetic Assessment of risk factors for venous thrombosis (MEGA)
study indicate a 1.9-fold higher risk of thrombosis with a 10mg
increase in estrogen dose (van Hylckama Vlieg, 2003). Concerning
the progestogen component, it was shown that combined oral con-
traceptives containing the third-generation progestogens gestodene
and desogestrel or the progestogen cyproterone acetate are more
thrombogenic than oral contraceptives containing the second-gener-
ation progestogen levonorgestrel. A recent meta-analysis concluded
that gestodene- and desogestrel-containing oral contraceptives
increases the risk of thrombosis by a factor 1.5–1.7 compared to
levonorgestrel-containing oral contraceptives (Kemmeren et al.,
2001). Oral contraceptives containing cyproterone acetate confer the
highest thrombotic risk, 3.9-fold higher than oral contraceptives
containing levonorgestrel (Vasilakis-Scaramozza and Jick, 2001).
Laboratory methods
Blood samples were taken from the antecubital vein in the morning
after an overnight abstinence from intake of food, caffeine and alco-
hol. Nine parts of blood were collected in one part 0.106 mol/l
sodium citrate (pH 5.8). Cell-free, citrated plasma was prepared by
centrifuging plasma at 2100g for 10 min at 188C, coded and
centrally stored at 2808C.
Normalized APC sensitivity ratios (nAPCsr) were determined by
quantifying the effect of APC on thrombin generation (thrombin
generation-based or ETP-based APC resistance test) as described
before (Rosing et al., 1997). SHBG was measured with an immuno-
metric assay (Immulite; DPC, USA). The sensitivity is 0.2 nmol/l;
the variation coefficient according to the manufacturer ranges from
5.8 to 13% for the inter-assay variation from high to very low
levels.
The samples were analysed in one series in random order. SHBG
levels and APC resistance were measured without knowledge of the
oral contraceptive used or any other of the participant’s character-
istics. The APC resistance test was performed in duplicate.
Statistical analysis
Mean SHBG plasma levels and mean nAPCsr in users of oral
contraceptives containing norethindrone, levonorgestrel, norgesti-
mate, gestodene, desogestrel, drospirenone or cyproterone acetate
were calculated. A scatter diagram and a regression line were
constructed with SHBG levels as the independent variable and
nAPCsr as the dependent variable. The degree of association
between SHBG levels and nAPCsr was measured by Pearson’s cor-
relation coefficient.
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Results
Between July and November 2002, 158 healthy women aged
18–51 years were recruited. We excluded two women, one
because of a history of diabetes mellitus and one because of
a history of venous thrombosis. Sixty women used a second-
generation oral contraceptive containing levonorgestrel, 49
women a third-generation oral contraceptive containing
gestodene, desogestrel or norgestimate, 23 women a drospire-
none-containing contraceptive pill, 22 women an oral contra-
ceptive containing cyproterone acetate and two women a
first-generation oral contraceptive containing norethindrone
(Table I).
Forty-six women agreed to switch from oral contraceptive
type, of whom 40 returned for a second blood donation. Five
women in the group of switchers discontinued due to breast
tenderness, increase in acne and hirsutism, pregnancy wish, a
previously unreported history of high blood pressure or
surgery. One woman was lost to follow-up. One participant
using a cyproterone acetate-containing pill was erroneously
prescribed the drospirenone pill instead of a levonorgestrel-
containing oral contraceptive and as a consequence excluded
from the analyses. During the study, none of the participants
experienced serious adverse events.
For the analyses of the first blood donation 156 women
were included, of whom 39 were included in the analysis of
the second blood donation. The various groups of oral contra-
ceptive users did not differ with respect to age and body
mass index (Table I).
Users of oral contraceptives with a moderately increased
risk, i.e. gestodene- and desogestrel-containing pills, had
SHBG plasma levels that were higher than for users of low-
risk oral contraceptives containing levonorgestrel (Table II).
Likewise, for higher doses of estrogen in oral contraceptives
we found higher SHBG levels, i.e. women using oral contra-
ceptives containing 30mg ethinylestradiol rendered higher
SHBG levels than women using oral contraceptives contain-
ing 20mg ethinylestradiol. The difference in SHBG levels
between third-generation pills containing gestodene and deso-
gestrel and second-generation pills containing levonorgestrel
was observed for both 20mg and 30mg ethinylestradiol oral
contraceptives. In the group of women taking pills containing
20mg ethinylestradiol, mean SHBG plasma levels were
111 nmol/l (95% CI 90–131) for users of gestodene pills and
143 nmol/l (95% CI 110–175) for users of desogestrel pills,
while for users of levonorgestrel pills mean SHBG levels
were 63 nmol/l (95% CI 36–91). Similarly, in the group of
women taking oral contraceptives containing 30mg ethinyl-
estradiol, mean SHBG levels were 136 nmol/l (95% CI
66–205) for users of gestodene pills and 164 nmol/l (95% CI
144–185) for users of desogestrel pills compared to
Table I. Participants’ characteristics
Progestogen Estrogen n Age (years) Body mass index (kg/m2)
Mean 95% CI Mean 95% CI
100mg LNG 20mg EE 5 22.2 18.1 to 26.3 21.9 19.8 to 23.9
75mg GTD 20mg EE 8 26.4 20.4 to 32.3 22.2 19.8 to 24.6
150mg DSG 20mg EE 13 30.1 25.0 to 35.1 24.5 21.8 to 27.2
150mg LNG 30mg EE 55 28.8 26.4 to 31.2 23.1 22.2 to 24.0
75mg GTD 30mg EE 4 26.0 14.9 to 37.1 23.1 20.6 to 25.5
150mg DSG 30mg EE 20 30.7 26.5 to 34.9 23.9 22.4 to 25.4
2 mg CPA 35mg EE 22 27.5 24.4 to 30.6 22.1 21.3 to 22.9
3 mg DRSP 30mg EE 23 27.6 24.7 to 30.4 24.4 22.9 to 25.8
250mg NGM 35mg EE 4 26.8 16.7 to 36.8 23.3 16.7 to 29.9
1 mg NET 35mg EE 2 30.0 271.7 to 131.7 20.6 19.9 to 21.2
CI ¼ confidence interval; LNG ¼ levonorgestrel; EE ¼ ethinylestradiol; GTD ¼ gestodene; DSG ¼ desogestrel;
CPA ¼ cyproterone acetate; DRSP ¼ drospirenone; NGM ¼ norgestimate; NET ¼ norethindrone.
Table II. Mean thrombin generation-based normalized activated protein C sensitivity ratios (nAPCsr) and mean sex
hormone-binding globulin (SHBG) levels in women using different types of oral contraceptives
Progestogen Estrogen n nAPCsr SHBG (nmol/l)
Mean 95% CI Mean 95% CI
100mg LNG 20mg EE 5 3.22 1.30 to 5.15 63 36 to 91
75mg GTD 20mg EE 8 3.40 2.52 to 4.28 111 90 to 131
150mg DSG 20mg EE 13 3.82 3.44 to 4.20 143 110 to 175
150mg LNG 30mg EE 55 2.97 2.69 to 3.25 63 59 to 67
75mg GTD 30mg EE 4 4.19 3.20 to 5.19 136 66 to 205
150mg DSG 30mg EE 20 4.24 3.68 to 4.79 164 144 to 185
2 mg CPA 35mg EE 22 4.00 3.74 to 4.26 210 182 to 238
3 mg DRSP 30mg EE 23 4.13 3.53 to 4.74 167 143 to 190
LNG ¼ levonorgestrel; EE ¼ ethinylestradiol; GTD ¼ gestodene; DSG ¼ desogestrel; CPA ¼ cyproterone acetate;
DRSP ¼ drospirenone.
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63 nmol/l (95% CI 59–67) for users of levonorgestrel pills.
For oral contraceptives with the highest risk of thrombosis,
i.e. cyproterone acetate-containing pills, we found the highest
SHBG levels (mean 210 nmol/l; 95% CI 182–238).
Women using oral contraceptives with a moderate or
highly increased thrombotic risk (desogestrel, gestodene and
cyproterone acetate pills) had higher nAPCsr than women
using oral contraceptives containing levonorgestrel (Table II).
Mean nAPCsr in the group of women using 20mg ethinyles-
tradiol oral contraceptives were 3.4 (95% CI 2.5–4.3) for
gestodene pills, 3.8 (95% CI 3.4–4.2) for desogestrel pills
compared to 3.2 (95% CI 1.3–5.2) for levonorgestrel pills. In
the groups of 30mg or 35mg ethinylestradiol oral contracep-
tive users mean nAPCsr were 4.2 (95% CI 3.2–5.2) for
gestodene-containing oral contraceptive users, 4.2 (95% CI
3.7–4.8) for desogestrel-containing oral contraceptive users
and 4.0 (95% CI 3.7–4.3) for cyproterone acetate-containing
oral contraceptive users, while for users of levonorgestrel-
containing oral contraceptives the mean nAPCsr was 3.0
(95% CI 2.7–3.3). Users of the recently introduced pill
containing drospirenone had a mean nAPCsr similar to that
of users of third-generation oral contraceptives (mean 4.1;
95% CI 3.5–4.7). After exclusion of 14 participants with the
factor V Leiden mutation and five participants with the
prothrombin 20210A mutation, mean nAPCsr for gestodene,
desogestrel, cyproterone acetate and drospirenone oral con-
traceptive users all remained markedly higher than for levo-
norgestrel oral contraceptive users (Table III).
In the 39 women who switched from oral contraceptive
type, SHBG levels and nAPCsr altered correspondingly, e.g.
SHBG levels and nAPCsr decreased when switching from
a cyproterone acetate-containing pill to a levonorgestrel-
containing pill, and similarly, SHBG and nAPCsr increased
when switching from an oral contraceptive containing levo-
norgestrel to an oral contraceptive containing drospirenone
(Table IV).
SHBG plasma levels were positively associated with
nAPCsr in the 156 oral contraceptive users, i.e. an increase
of SHBG levels of 100 nmol/l was associated with an
increase of nAPCsr of 0.7 (95% CI 0.4–0.9) over the range
of measurements made. Pearson’s correlation coefficient was
0.4 (P , 0.001). After exclusion of 14 women with the factor
V Leiden and five women with the prothrombin 20210A
mutation, the beta of the regression equation slightly
decreased, i.e. an elevation of SHBG levels of 100 nmol/l
was associated with an elevation of the nAPCsr of 0.6 (95%
CI 0.4–0.8) over the range of measurements made (Figure
1). Pearson’s correlation coefficient increased to 0.5
(P , 0.001).
Discussion
In this study of SHBG plasma levels and prothrombotic
effects among 156 healthy users of various types of oral con-
traceptives, we observed a positive association between the
effect of an oral contraceptive on SHBG levels or
Table III. Mean thrombin generation-based normalized activated protein C sensitivity ratios (nAPCsr) and mean sex hormone-binding globulin (SHBG) levels
in women without the factor V Leiden or prothrombin 20210A mutation using different types of oral contraceptives
Progestogen Estrogen n nAPCsr SHBG (nmol/l)
Mean 95% CI Mean 95% CI
100mg LNG 20mg EE 4 2.55 1.80 to 3.31 68 33 to 103
75mg GTD 20mg EE 7 3.12 2.43 to 3.81 112 88 to 136
150mg DSG 20mg EE 12 3.91 3.55 to 4.27 144 109 to 179
150mg LNG 30mg EE 52 2.78 2.59 to 2.98 63 59 to 68
75mg GTD 30mg EE 3 4.18 2.29 to 6.08 137 4 to 270
150mg DSG 30mg EE 16 3.96 3.56 to 4.35 163 138 to 189
2 mg CPA 35mg EE 21 3.96 3.70 to 4.23 209 180 to 238
3 mg DRSP 30mg EE 19 3.69 3.22 to 4.17 168 140 to 195
LNG ¼ levonorgestrel; EE ¼ ethinylestradiol; GTD ¼ gestodene; DSG ¼ desogestrel; CPA ¼ cyproterone acetate; DRSP ¼ drospirenone.
Table IV. Change in thrombin generation-based normalized activated protein C sensitivity ratios (nAPCsr) and sex hormone-binding globulin (SHBG) levels
in women switching from oral contraceptive type
Oral contraceptive n Mean nAPCsr Mean SHBG (nmol/l)
Before After Before After Difference (95% CI) Before After Difference (95% CI)
100mg LNG/20mg EE 3 mg DRSP/30mg EE 1 2.49 2.79 þ0.30 (2) 43 120 þ77 (2)
150mg LNG/30mg EE 3 mg DRSP/30mg EE 13 3.18 3.66 þ0.47 (þ0.15 to þ0.80) 63 144 þ81 (þ61 to þ101)
3 mg DRSP/30mg EE 150mg LNG/30mg EE 5 3.55 2.73 20.83 (21.80 to þ0.15) 157 80 277 (2129 to 225)
2 mg CPA/35mg EE 150mg LNG/30mg EE 6 3.96 3.00 20.96 (21.66 to 20.26) 235 85 2150 (2206 to 294)
150mg DSG/20mg EE 3 mg DRSP/30mg EE 4 3.50 3.90 þ0.40 (20.20 to þ1.00) 189 215 þ25 (þ6 to þ44)
150mg DSG/30mg EE 3 mg DRSP/30mg EE 4 4.07 4.04 20.03 (20.32 to þ0.27) 147 181 þ34 (0 to þ68)
75mg GTD/20mg EE 3 mg DRSP/30mg EE 3 2.78 2.79 þ0.01 (22.45 to þ2.47) 104 120 þ16 (291 to þ122)
250mg NGM/35mg EE 3 mg DRSP/30mg EE 2 4.61 4.93 þ0.31 (20.99 to þ1.62) 123 183 þ61 (222 to þ143)
1 mg NET/35mg EE 3 mg DRSP/30mg EE 1 3.73 2.36 21.38 (2) 138 306 þ168 (2)
LNG ¼ levonorgestrel; DRSP ¼ drospirenone; EE ¼ ethinylestradiol; DSG ¼ desogestrel; GTD ¼ gestodene; NGM ¼ norgestimate; NET ¼ norethindrone;
CPA ¼ cyproterone acetate.
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estrogenicity of the formulation and the thrombotic risk of a
formulation as reported in the literature. Users of oral contra-
ceptives with a moderately increased risk, i.e. third-gener-
ation oral contraceptives containing gestodene or desogestrel,
had SHBG levels that were higher than in users of low-risk,
second-generation oral contraceptives containing levonorges-
trel (Vandenbroucke et al., 2001). Similarly, for higher doses
of estrogen in oral contraceptives, we observed higher SHBG
plasma levels (Rosendaal et al., 2003). Users of oral contra-
ceptives with the highest risk of thrombosis, i.e. cyproterone
acetate-containing pills, also rendered the highest SHBG
levels (Vasilakis-Scaramozza and Jick, 2001).
In addition, SHBG plasma levels were positively associ-
ated with the resistance to the anticoagulant action of APC
determined with a thrombin generation-based APC resistance
test, i.e. high SHBG levels were related to a high resistance
to APC. The thrombin generation-based APC resistance test
that we used in this study predicts the risk of thrombosis in
users of oral contraceptives as well as in non-users and men,
so the relationship between SHBG plasma levels and APC
resistance supports the hypothesis that SHBG is a marker for
the thrombotic risk of an oral contraceptive (Tans et al.,
2003).
The differences in SHBG levels and resistance to APC
were not the result of differences between women rather than
between type of oral contraceptive, as indicated by the results
in women who switched from oral contraceptive type.
Switching from a highly thrombogenic pill containing cypro-
terone acetate to a less thrombogenic pill containing levonor-
gestrel resulted in a decrease of SHBG levels as well as APC
resistance.
Recently, Kemmeren et al., (2004) postulated that the
different effects of third- and second-generation oral contra-
ceptives on the anticoagulant pathway might be explained by
the observation that the effect of ethinylestradiol on anticoa-
gulant parameters is less well counteracted by desogestrel
than by levonorgestrel. In their study, progestogen-only pills
did not induce changes of anticoagulant parameters or induce
changes opposite to those of combined oral contraceptives
containing the same dose of progestogen (Kemmeren et al.,
2004). The divergent effects of estrogen and progestogens
have also been observed with regard to SHBG, i.e. progesto-
gen-only pills decrease SHBG in contrast with combined oral
contraceptives or estrogen alone which increase SHBG levels
(van Kammen et al., 1975; El Makhzangy et al., 1979; Crona
et al., 1984). In agreement with the effect on anticoagulant
parameters, the lowering effect on SHBG is more pro-
nounced in pills containing only levonorgestrel compared to
pills containing only desogestrel (Crona et al., 1984;
Barkfeldt et al., 2001; Kemmeren et al., 2004).
In conclusion, our findings support the hypothesis that the
increase of SHBG induced by a combined oral contraceptive
could be interpreted as a measure of estrogenicity of a com-
bined oral contraceptive and that estrogenicity is a factor
influencing the thrombotic risk of an oral contraceptive.
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